Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/30/2025 07:53 PDT] GNTA Expected to Trade Up After Bullish Patterns Develop
• [04/16/2025 07:17 PDT] GNTA Expected to Trade Up After Bullish Patterns Develop
• [04/11/2025 07:27 PDT] GNTA Expected to Trade Up After Bullish Patterns Develop
• [03/24/2025 10:29 PDT] Genenta Science S.p.A. (NASDAQ:GNTA), Up By 100% ($3.8) From $3.8 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [03/13/2025 07:12 PDT] GNTA Expected to Trade Up After Bullish Patterns Develop
• [03/10/2025 07:52 PDT] GNTA Expected to Trade Up After Bullish Patterns Develop